The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
An open, multicenter, phase II clinical trial to evaluate efficacy and safety of S-1 split cisplatin in patients with advanced gastric cancer (AGC): HGCSG0702—Safety analysis.
Ichiro Iwanaga
No relevant relationships to disclose
Satoshi Yuki
No relevant relationships to disclose
Hiraku Fukushima
No relevant relationships to disclose
Atsushi Ishiguro
No relevant relationships to disclose
Takenori Takahata
No relevant relationships to disclose
Takuto Miyagishima
No relevant relationships to disclose
Mineo Kudo
No relevant relationships to disclose
Yasuko Uehata
No relevant relationships to disclose
Yuh Sakata
Research Funding - Bristol-Myers Squibb; Daiichi Sankyo; Merck Serono; Otsuka; Taiho Pharmaceutical; Yakult Honsha
Yoshito Komatsu
Research Funding - Chugai Pharma; Daiichi Sankyo; GlaxoSmithKline; Novartis; Pfizer; Taiho Pharmaceutical; Yakult Honsha